Aspira Women's Health Inc.
AWHL · OTCMCIK 926617fmd_016JBRKAA6GM370EMEDXXXVAGAManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2010 to Jun 30, 2026, 65 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 3 | 3 | 3 | 5 | 5 | 7 | 8 | 87 | 9 | 9 |
| Cost of revenue | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 |
| Net interest income | (0) | (0) | (0) | 0 | 0 | (0) | 0 | 0 | (0) | (0) |
| Gross profit | (0) | 0 | (0) | 1 | 1 | 3 | 4 | 5 | 5 | 6 |
| Realized investment gains (losses) | – | – | – | – | – | – | – | – | – | – |
| Research and development | 2 | 1 | 1 | 1 | 2 | 5 | 6 | 4 | 3 | 3 |
| Selling, general and administrative | 13 | 10 | 11 | 15 | 17 | 30 | 30 | 20 | 18 | 11 |
| Total operating expenses | 15 | 11 | 11 | 16 | 19 | 36 | 35 | 24 | 22 | 14 |
| Operating income | (15) | (10) | (11) | (15) | (18) | (33) | (31) | (19) | (16) | (8) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 0 | (0) | (0) | (0) | 0 | 1 | 1 | 2 | 3 | (5) |
| Income before taxes | – | – | – | 15 | 18 | 32 | 30 | 17 | (13) | (13) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – |
| Net income from continuing operations | – | – | – | 15 | 18 | – | – | – | – | – |
| Net income | (15) | (10) | (11) | (15) | (18) | (32) | (30) | (17) | (13) | (13) |
| Net income to common shareholders | (15) | (11) | (11) | (15) | (18) | (32) | (30) | – | – | – |